Phase 1/2Completed
Comparative Bioavailability of Intranasal Epinephrine
A Study to Compare the Bioavailability of Epinephrine Following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6mg, and 4mg With EpiPen 0.3mg Intramuscular Injection in Healthy Adults
- Sponsor
- Nasus Pharma (Industry)
- Enrollment
- 12 enrolled
- Conditions
- Anaphylaxis; Anaphylactic Reaction
- Interventions
- A: Epinephrine injection; B: FMXIN002 3.6mg; C: FMXIN002 4.0mg
- Ages
- adults
- Registry
- NCT06205134
Full record on ClinicalTrials.gov
From the registry
A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6 mg, and 4mg with EpiPen 0.3mg Intramuscular Injection in Healthy Adults
Primary outcomes
- Bioavailability of Epinephrine
- Blood pressure
- Heart rate
- Respiratory rate
History
Last registry update
Study completion
Primary completion
Registered
Started